Cellular Dynamics International Inc.
This article was originally published in Start Up
Executive Summary
Cellular Dynamics International Inc. is using induced pluripotent stem (iPS) cells, derived from adult cells, as drug discovery and development tools. The company is initially pursuing the cardiotoxicity market with iCell cardiomyocytes, which closely resemble in vivo cardiomyocytes, even beating in unison in a cell culture dish. When exposed to drugs or other external agents, the cells produce electrophysiological and biochemical responses typical of in vivo cardiomyocytes.
You may also be interested in...
Start-Up Previews (03/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Transdermal Drug Delivery: More Than Skin Deep, features profiles of AllTranz, Ocelus, Quinnova and Syntropharma. Plus these Start-Ups Across Health Care: Apnex Medical, Cellular Dynamics, Helix Therapeutics, Presym and Vatrix Medical.
Start-Up Previews (03/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Transdermal Drug Delivery: More Than Skin Deep, features profiles of AllTranz, Ocelus, Quinnova and Syntropharma. Plus these Start-Ups Across Health Care: Apnex Medical, Cellular Dynamics, Helix Therapeutics, Presym and Vatrix Medical.
Making Inroads in Predictive Toxicology
Given the current "Safety First" mind-set among regulators, it's not surprising that the field of predictive toxicology has been slow to gain traction. Despite significant progress in developing biomarkers, database tools, and other methods, pharma companies continue to rely heavily on traditional methods for assessing potential drug toxicities. Even if investors are shy now, many say that they will eventually be a beneficiary of predictive toxicology, and that comes as good news to start-ups in the space.